Gossamer Bio (NASDAQ:GOSS - Get Free Report)'s stock had its "buy" rating reissued by research analysts at HC Wainwright in a report released on Thursday,Benzinga reports. They presently have a $10.00 price target on the stock. HC Wainwright also issued estimates for Gossamer Bio's FY2029 earnings at $0.59 EPS.
Gossamer Bio Trading Up 4.2 %
Shares of NASDAQ:GOSS traded up $0.04 during trading on Thursday, reaching $1.04. 843,173 shares of the stock were exchanged, compared to its average volume of 947,638. The firm's 50-day moving average price is $0.87 and its 200 day moving average price is $0.90. The firm has a market cap of $234.53 million, a price-to-earnings ratio of -3.20 and a beta of 1.81. Gossamer Bio has a 12-month low of $0.50 and a 12-month high of $1.60. The company has a debt-to-equity ratio of 3.64, a quick ratio of 6.74 and a current ratio of 6.74.
Gossamer Bio (NASDAQ:GOSS - Get Free Report) last released its quarterly earnings data on Thursday, November 7th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.04. The business had revenue of $9.48 million for the quarter, compared to analysts' expectations of $4.52 million. On average, sell-side analysts anticipate that Gossamer Bio will post -0.28 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Gossamer Bio
A number of institutional investors and hedge funds have recently added to or reduced their stakes in GOSS. US Bancorp DE acquired a new position in shares of Gossamer Bio in the third quarter worth about $39,000. GSA Capital Partners LLP acquired a new position in shares of Gossamer Bio in the 3rd quarter valued at approximately $67,000. Algert Global LLC purchased a new position in shares of Gossamer Bio during the 2nd quarter valued at approximately $75,000. Sequoia Financial Advisors LLC grew its position in shares of Gossamer Bio by 26.7% during the third quarter. Sequoia Financial Advisors LLC now owns 118,500 shares of the company's stock worth $117,000 after buying an additional 25,000 shares in the last quarter. Finally, The Manufacturers Life Insurance Company increased its stake in shares of Gossamer Bio by 67.4% in the second quarter. The Manufacturers Life Insurance Company now owns 310,213 shares of the company's stock worth $279,000 after buying an additional 124,913 shares during the last quarter. 81.23% of the stock is owned by hedge funds and other institutional investors.
Gossamer Bio Company Profile
(
Get Free Report)
Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.
Featured Stories
Before you consider Gossamer Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gossamer Bio wasn't on the list.
While Gossamer Bio currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
